Clinical Trials
A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin®) In Postmenopausal Hr+ PatientsCondition: Breast CancerIntervention: Drug: Aromasin Sponsor: Pfizer Terminated Mon, 28 Feb 2011 12:00:00 EST Special Investigation For Patients With Renal And/Or Hepatic Disorders On AromasinCondition: Breast NeoplasmsIntervention: Drug: Exemestane Sponsor: Pfizer Completed Fri, 03 Jul 2009 12:00:00 EDT Exemestane in Advanced and Recurrent Endometrial CarcinomaCondition: Endometrial CancerIntervention: Drug: Exemestane Sponsor: Nordic Society of Gynaecological Oncology - Clinical Trials Unit Completed Fri, 18 Oct 2013 12:00:00 EDT A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast CancerCondition: Invasive Early Breast CancerIntervention: Drug: Aromasin Sponsor: Pfizer Terminated Wed, 12 May 2010 12:00:00 EDT Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast CancerCondition: Breast NeoplasmsIntervention: Drug: Aromasin Sponsor: Pfizer Terminated Thu, 11 Nov 2010 12:00:00 EST Prospective Study of UDP-gluconoryltransferase 2B17 Genotype as a Predictive Marker of Exemestane PK and PDCondition: Breast CarcinomaIntervention: Drug: Exemestane Sponsor: National University Hospital, Singapore Unknown status Wed, 01 Aug 2012 12:00:00 EDT An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With AromasinCondition: Breast NeoplasmsIntervention: Other: Aromasin Sponsor: Pfizer Terminated Tue, 21 Oct 2008 12:00:00 EDT Adjuvant Post-Tamoxifen Exemestane TrialCondition: Breast CancerIntervention: Drug: exemestane Sponsor: Hellenic Breast Surgeons Society Terminated Thu, 18 Dec 2008 12:00:00 EST Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer PatientsCondition: Early Breast CancerIntervention: Other: Aromasin (exemestane) Sponsor: Pfizer Terminated Thu, 01 Jul 2010 12:00:00 EDT Exemestane in Post-Menopausal Women With NSCLCCondition: Non-Small Cell Lung CancerIntervention: Drug: Exemestane Sponsor: Masonic Cancer Center, University of Minnesota Recruiting Thu, 28 Jan 2016 12:00:00 EST 
Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By ExemestaneCondition: Breast NeoplasmsInterventions: Drug: exemestane (Aromasin); Drug: tamoxifen + exemestane Sponsor: Pfizer Completed Thu, 09 May 2002 12:00:00 EDT Pivotal Bioequivalence Study of Exemestane 25 mg Tablets Under Fasting Conditions in Healthy SubjectsCondition: HealthyInterventions: Drug: Reference product (A) Aromasin (Exemestane); Drug: Test product (B) Exemestane Sponsor: Actavis Inc. Withdrawn Fri, 04 Jan 2013 12:00:00 EST Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast CancerCondition: Hormone Receptor Positive Malignant Neoplasm of BreastInterventions: Drug: Exemestane; Drug: Everolimus Sponsor: Organisation for Oncology and Translational Research Unknown status Wed, 01 Jan 2014 12:00:00 EST Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast CancerCondition: Breast CancerIntervention: Drug: Aromasin Sponsor: Pfizer Completed Tue, 12 Jan 2010 12:00:00 EST Exemestane With Sunitinib (SUTENT®) in Metastatic Breast CancerCondition: Metastatic Breast CancerInterventions: Drug: Exemestane; Drug: Sutent Sponsors: Baylor Breast Care Center; Pfizer Terminated Wed, 20 May 2009 12:00:00 EDT Exemestane and Cyclophosphamide for Metastatic Breast CancerCondition: Metastatic Beast CancerInterventions: Drug: Exemestane; Drug: Cyclophosphamide Sponsor: NYU Langone Health Completed Wed, 16 Oct 2013 12:00:00 EDT Efficacy and Safety of TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Breast CancerCondition: Breast CancerIntervention: Drug: Exemestane Sponsor: Tianjin Medical University Unknown status Tue, 24 Jul 2012 12:00:00 EDT Bioequivalency Study of Exemestane 25 mg Tablet Under Fed ConditionsCondition: Breast CancerIntervention: Drug: exemestane Sponsor: Roxane Laboratories Completed Fri, 08 Apr 2011 12:00:00 EDT Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted ConditionsCondition: Breast CancerIntervention: Drug: exemestane Sponsor: Roxane Laboratories Completed Fri, 08 Apr 2011 12:00:00 EDT Pilot Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted ConditionsCondition: Breast CancerIntervention: Drug: exemestane Sponsor: Roxane Laboratories Completed Fri, 08 Apr 2011 12:00:00 EDT
Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast CancerCondition: Breast NeoplasmsInterventions: Drug: Exemestane; Dietary Supplement: Calcium carbonate; Dietary Supplement: Vitamin D Sponsors: Georgetown University; National Cancer Institute (NCI) Completed Mon, 17 Nov 2003 12:00:00 EST Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast CancerConditions: Breast Cancer; Estrogen Receptor-Positive Breast Cancer; Breast Cancer, Estrogen Receptor-Positive; ER+ Breast CancerInterventions: Drug: entinostat; Drug: exemestane; Drug: Placebo Sponsor: Syndax Pharmaceuticals Completed Tue, 13 May 2008 12:00:00 EDT Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On TamoxifenCondition: Breast NeoplasmsInterventions: Drug: Exemestane; Drug: Celecoxib + Exemestane Sponsor: Pfizer Completed Thu, 30 May 2002 12:00:00 EDT Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule FindingCondition: Breast CancerInterventions: Drug: BIIB021; Drug: exemestane (Aromasin) Sponsor: Biogen Completed Thu, 29 Oct 2009 12:00:00 EDT Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In ChinaCondition: Breast NeoplasmsIntervention: Drug: Aromasin (exemestane) Sponsor: Pfizer Completed Fri, 06 Aug 2010 12:00:00 EDT Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST)Condition: Post Menopausal Women With Early Breast CancerIntervention: Drug: Aromasin (exemestane) Sponsor: Pfizer Completed Fri, 15 Jan 2010 12:00:00 EST Exemestane-RAD001-MetforminCondition: Breast CancerInterventions: Drug: Everolimus; Drug: Exemestane; Drug: Metformin Sponsors: M.D. Anderson Cancer Center; Susan G. Komen Breast Cancer Foundation Terminated Mon, 25 Jun 2012 12:00:00 EDT Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast CancerCondition: Her2 Negative Breast Cancer PatientsInterventions: Drug: MM-121; Drug: Placebo; Drug: Exemestane Sponsor: Merrimack Pharmaceuticals Completed Fri, 25 Jun 2010 12:00:00 EDT Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast CancerCondition: Breast CancerInterventions: Drug: Enzalutamide; Drug: exemestane; Drug: Placebo (for enzalutamide) Sponsors: Pfizer; Astellas Pharma Inc; Medivation, Inc. Active, not recruiting Tue, 10 Dec 2013 12:00:00 EST Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast CancerCondition: Metastatic Breast CancerInterventions: Drug: Megestrol acetate; Drug: exemestane (Aromasin) Sponsor: Pfizer Completed Tue, 09 Nov 2010 12:00:00 EST
Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial CancerConditions: Atypical Hyperplasia; Endometrial Atypical Hyperplasia /Endometrioid Intraepithelial Neoplasia; FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma; FIGO Grade 2 Endometrial Endometrioid AdenocarcinomaInterventions: Drug: Exemestane; Other: Laboratory Biomarker Analysis; Other: Pharmacokinetic Study; Other: Questionnaire Administration Sponsor: National Cancer Institute (NCI) Active, not recruiting Tue, 03 Oct 2017 12:00:00 EDT Exemestane in Hormone Receptor Positive High Grade Ovarian CancerCondition: Ovarian CancerInterventions: Drug: Exemestane; Other: Placebo oral tablet Sponsors: Ente Ospedaliero Ospedali Galliera; Istituto Di Ricerche Farmacologiche Mario Negri; Fondazione Policlinico Universitario Agostino Gemelli IRCCS; Federation of Italian Cooperative Oncology Groups Recruiting Wed, 08 Jul 2020 12:00:00 EDT A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)Condition: Breast NeoplasmsInterventions: Drug: Ridaforolimus; Drug: Dalotuzumab; Drug: Exemestane Sponsor: Merck Sharp & Dohme Corp. Completed Thu, 24 May 2012 12:00:00 EDT Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast CancerCondition: Breast CancerInterventions: Drug: Chidamide; Drug: exemestane; Drug: placebo Sponsor: Chipscreen Biosciences, Ltd. Active, not recruiting Fri, 26 Jun 2015 12:00:00 EDT The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast CancerConditions: Locally Advanced Breast Cancer; Metastatic Breast CancerInterventions: Drug: Fulvestrant; Drug: Exemestane Sponsor: AstraZeneca Completed Wed, 23 Jul 2003 12:00:00 EDT A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast CancerCondition: Breast NeoplasmsIntervention: Drug: exemestane Sponsor: Pfizer Completed Tue, 01 Apr 2008 12:00:00 EDT Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast CancerConditions: Breast Cancer; Estrogen Receptor Positive Breast CancerInterventions: Drug: entinostat; Drug: exemestane Sponsor: Syndax Pharmaceuticals Unknown status Fri, 01 Jul 2016 12:00:00 EDT Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast CancerCondition: Breast CancerInterventions: Drug: Exemestane; Drug: Celecoxib; Other: Correlative studies Sponsors: Ohio State University Comprehensive Cancer Center; Pfizer Completed Tue, 20 Sep 2005 12:00:00 EDT Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast CancerCondition: Breast CancerInterventions: Drug: Exemestane; Drug: Fulvestrant Sponsors: Ohio State University Comprehensive Cancer Center; Pfizer Completed Tue, 20 Sep 2005 12:00:00 EDT GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast CancerCondition: Advanced Estrogen Receptor Positive HER2- Breast CancerInterventions: Drug: GS-5829; Drug: Exemestane; Drug: Fulvestrant Sponsor: Gilead Sciences Terminated Tue, 06 Dec 2016 12:00:00 EST
Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast CancerCondition: Metastatic Breast CancerInterventions: Drug: placebo; Drug: Celecoxib; Drug: Exemestane Sponsor: ARCAGY/ GINECO GROUP Completed Wed, 05 Sep 2007 12:00:00 EDT Exemestane (Aromasine) + Tamoxifen - Breast Neo-AdjuvantCondition: Breast NeoplasmsInterventions: Drug: Exemestane; Drug: tamoxifen Sponsors: Institut Claudius Regaud; PHARMACIA SAS Completed Fri, 12 Jun 2009 12:00:00 EDT Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast CancerCondition: Premenopausal Breast CancerIntervention: Drug: Pembrolizumab/ Exemestane/ Leuprolide Sponsors: National Taiwan University Hospital; Merck Sharp & Dohme Corp. Recruiting Tue, 13 Dec 2016 12:00:00 EST Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast CancerCondition: Breast NeoplasmsInterventions: Drug: exemestane; Drug: tamoxifen Sponsor: Pfizer Completed Thu, 19 Jan 2006 12:00:00 EST Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast CancerCondition: Breast NeoplasmsInterventions: Drug: PF-04691502; Drug: Exemestane Sponsor: Pfizer Withdrawn Mon, 06 Aug 2012 12:00:00 EDT An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker AnalysisCondition: Oestrogen Receptor Positive Advanced Breast CancerInterventions: Drug: RAD001; Drug: Exemestane Sponsor: Novartis Pharmaceuticals Completed Thu, 06 Dec 2012 12:00:00 EST Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer PatientsCondition: Breast CancerInterventions: Drug: Exemestane; Drug: Anastrozole Sponsors: Spanish Breast Cancer Research Group; Pfizer Completed Wed, 10 Aug 2005 12:00:00 EDT Study of Aspirin and Exemestane as Adjuvant Treatment in Breast CancerCondition: Breast NeoplasmsInterventions: Drug: aspirin; Drug: Exemestane Sponsor: Chinese Academy of Medical Sciences Unknown status Fri, 09 Sep 2011 12:00:00 EDT Neoadjuvant Tucidinostat and Exemestane in Early Breast CancerCondition: Breast CancerInterventions: Drug: Tucidinostat; Drug: Exemestane; Drug: Ovarian function suppression Sponsor: First Affiliated Hospital, Sun Yat-Sen University Recruiting Thu, 09 Jul 2020 12:00:00 EDT Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer PatientsCondition: Breast CancerInterventions: Drug: Fulvestrant 500 mg; Drug: Exemestane 25 mg Sponsors: Chinese Academy of Medical Sciences; Cancer Institute and Hospital, Chinese Academy of Medical Sciences Unknown status Wed, 06 Jan 2016 12:00:00 EST
Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast CancerConditions: Stage 0 Breast Cancer AJCC v6 and v7; Stage I Breast Cancer AJCC v7; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7Interventions: Drug: Exemestane; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Other: Placebo Administration; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Procedure: Therapeutic Conventional Surgery Sponsor: National Cancer Institute (NCI) Active, not recruiting Fri, 06 Nov 2015 12:00:00 EST Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With ExemestaneConditions: Hormone Receptor Positive Malignant Neoplasm of Breast; Metastatic Breast CancerIntervention: Drug: Everolimus plus Exemestane Sponsors: VU University Medical Center; Borstkanker Onderzoek Groep; Novartis Unknown status Thu, 10 Apr 2014 12:00:00 EDT A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase InhibitorCondition: Advanced Breast CancerInterventions: Drug: Everolimus; Drug: Exemestane; Drug: Everolimus Placebo Sponsor: Novartis Pharmaceuticals Active, not recruiting Wed, 18 Oct 2017 12:00:00 EDT Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast CancerCondition: Advanced Breast CancerInterventions: Drug: Entinostat; Drug: Placebo; Drug: Exemestane Sponsor: Taizhou EOC Pharma Co., Ltd. Active, not recruiting Tue, 29 May 2018 12:00:00 EDT Exemestane or Docetaxel-Cytoxan in Low Recurrence Score CancersCondition: Breast CancerInterventions: Drug: Exemestane; Drug: Docetaxel; Drug: Cytoxan Sponsors: Emory University; Pfizer Completed Fri, 17 Jul 2009 12:00:00 EDT Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast CancerCondition: Neoadjuvant Treatment for HER2-positive, ER-positive Breast CancerIntervention: Drug: palbociclib and exemestane plus trastuzumab and pyrotinib Sponsor: Guangdong Provincial People's Hospital Not yet recruiting Mon, 26 Apr 2021 12:00:00 EDT Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast CancerCondition: Breast CancerInterventions: Drug: exemestane; Drug: Placebo Sponsor: NCIC Clinical Trials Group Completed Thu, 07 Aug 2003 12:00:00 EDT Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate CancerCondition: Prostate CancerInterventions: Drug: Exemestane; Drug: Exemestane+bicalutamide Sponsor: Swiss Group for Clinical Cancer Research Completed Tue, 01 Jul 2003 12:00:00 EDT Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast CancerCondition: Breast CancerIntervention: Drug: exemestane Sponsors: NCIC Clinical Trials Group; Grupo Espanol de Investigacion del Cancer de Mama; UNICANCER Completed Mon, 17 May 2004 12:00:00 EDT Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or AnastrozoleCondition: Breast CancerInterventions: Drug: Everolimus; Drug: Exemestane; Drug: Everolimus Placebo Sponsor: Novartis Pharmaceuticals Completed Wed, 18 Mar 2009 12:00:00 EDT
Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast CancerConditions: Metastatic Breast Cancer; Breast Cancer; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Locally Advanced Malignant NeoplasmInterventions: Drug: Everolimus; Drug: Exemestane; Drug: Fulvestrant Sponsors: Consorzio Oncotech; Clinical Research Technology S.r.l. Unknown status Tue, 31 Mar 2015 12:00:00 EDT Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV Epithelial Ovarian CancerCondition: Ovarian CancerIntervention: Drug: Exemestane Sponsor: Ottawa Hospital Research Institute Completed Fri, 02 Dec 2005 12:00:00 EST The Impact of Obesity and Obesity Treatments on Breast CancerCondition: Breast CancerInterventions: Drug: Exemestane; Drug: Avandamet Sponsors: M.D. Anderson Cancer Center; Susan G. Komen Breast Cancer Foundation Completed Tue, 07 Jul 2009 12:00:00 EDT Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic TumorsConditions: Neoplasms; Breast Neoplasms; Kidney Neoplasms; Pancreatic Neuroendocine Neoplasms (pNETs)Interventions: Drug: alpelisib; Drug: everolimus; Drug: exemestane Sponsor: Novartis Pharmaceuticals Completed Tue, 04 Mar 2014 12:00:00 EST Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer PatientsCondition: Breast NeoplasmsIntervention: Drug: exemestane (Aromasin®) Sponsor: Pfizer Completed Thu, 15 Sep 2005 12:00:00 EDT Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast CancerCondition: Breast NeoplasmsInterventions: Drug: exemestane; Drug: anastrozole Sponsor: Pfizer Completed Fri, 02 Sep 2005 12:00:00 EDT Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal WomenCondition: Breast NeoplasmsIntervention: Drug: exemestane Sponsor: Pfizer Terminated Thu, 20 Jun 2002 12:00:00 EDT Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 TumorsConditions: Breast Cancer; Stage II Breast Cancer; Stage III Breast CancerInterventions: Drug: Exemestane; Drug: Exemestane and tamoxifen Sponsor: University of Colorado, Denver Active, not recruiting Mon, 15 Apr 2013 12:00:00 EDT Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast CancerCondition: Advanced Breast CancerInterventions: Drug: Bosutinib; Drug: exemestane; Drug: Exemestane Sponsor: Pfizer Terminated Wed, 19 Nov 2008 12:00:00 EST Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast CancerCondition: Breast CancerIntervention: Drug: Everolimus and exemestane Sponsor: Novartis Healthcare A/S Completed Mon, 30 Dec 2013 12:00:00 EST
Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast CancerCondition: Breast CancerInterventions: Drug: anastrozole; Drug: exemestane Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; Southwest Oncology Group; International Breast Cancer Study Group Completed Thu, 07 Aug 2003 12:00:00 EDT RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast CancerConditions: Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast CancerInterventions: Drug: Exemestane; Drug: Gamma-Secretase Inhibitor RO4929097; Drug: Goserelin Acetate Sponsor: National Cancer Institute (NCI) Terminated Wed, 23 Jun 2010 12:00:00 EDT Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast CancerCondition: Solid Tumors and LymphomasInterventions: Drug: Alobresib; Drug: Exemestane; Drug: Fulvestrant Sponsor: Gilead Sciences Completed Thu, 19 Mar 2015 12:00:00 EDT Palbociclib With Everolimus + Exemestane In BCConditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Hormone Receptor (HR)-Positive Breast CancerInterventions: Drug: Palbociclib; Drug: Everolimus; Drug: Exemestane Sponsors: Dana-Farber Cancer Institute; Pfizer Active, not recruiting Thu, 18 Aug 2016 12:00:00 EDT Exemestane in Treating Postmenopausal Women With Stage IV Breast CancerCondition: Breast CancerInterventions: Drug: exemestane; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment; Other: immunohistochemistry staining method Sponsors: City of Hope Medical Center; National Cancer Institute (NCI) Completed Thu, 18 Dec 2008 12:00:00 EST Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast CancerCondition: Breast CancerInterventions: Drug: Exemestane + Dasatinib; Drug: Exemestane + Placebo Sponsor: Bristol-Myers Squibb Completed Tue, 07 Oct 2008 12:00:00 EDT A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast CancerCondition: Breast NeoplasmsInterventions: Drug: exemestane; Drug: sunitinib malate Sponsor: Pfizer Terminated Thu, 04 Jan 2007 12:00:00 EST Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL WomenCondition: Breast CancerInterventions: Drug: Everolimus; Drug: Exemestane Sponsors: Jules Bordet Institute; Novartis Unknown status Tue, 07 Jan 2014 12:00:00 EST Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast CancerCondition: Breast CancerInterventions: Drug: exemestane; Drug: tamoxifen; Drug: triptorelin Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Breast International Group Active, not recruiting Thu, 07 Aug 2003 12:00:00 EDT Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)Condition: Progression-free SurvivalInterventions: Drug: fulvestrant; Drug: anastrozole; Drug: exemestane Sponsor: AstraZeneca Completed Thu, 23 Jul 2009 12:00:00 EDT
Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast CancerConditions: Primary Breast Cancer ER+ve; Primary Breast Cancer AR+ve TNBNInterventions: Drug: Enzalutamide; Drug: Exemestane Sponsors: Queen Mary University of London; Astellas Pharma Inc Active, not recruiting Tue, 09 Feb 2016 12:00:00 EST BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast CancerCondition: Metastatic or Locally-advanced Unresectable Breast CancerInterventions: Drug: BYL719; Drug: Letrozole; Drug: Exemestane Sponsors: Memorial Sloan Kettering Cancer Center; Novartis Pharmaceuticals Active, not recruiting Thu, 06 Jun 2013 12:00:00 EDT Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast CancerCondition: Post Menopausal Breast CancerInterventions: Drug: everolimus; Drug: exemestane Sponsor: Novartis Pharmaceuticals Completed Mon, 05 Jun 2017 12:00:00 EDT Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast CancerCondition: Breast NeoplasmsInterventions: Drug: Radium-223 dichloride (Xofigo, BAY88-8223); Drug: Placebo (saline); Drug: Exemestane; Drug: Everolimus Sponsor: Bayer Active, not recruiting Tue, 07 Oct 2014 12:00:00 EDT A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.Condition: Breast CancerInterventions: Drug: Capecitabine; Drug: Exemestane; Drug: Everolimus Sponsor: Novartis Pharmaceuticals Completed Tue, 05 Feb 2013 12:00:00 EST Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of DiseaseCondition: Breast CancerInterventions: Drug: Raloxifene followed by combination therapy; Drug: Exemestane followed by combination therapy Sponsors: Memorial Sloan Kettering Cancer Center; Pharmacia Completed Tue, 20 Sep 2005 12:00:00 EDT Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast CancerCondition: Hormone-receptor Positive Breast CancerIntervention: Drug: exemestane and pazopanib Sponsor: GlaxoSmithKline Withdrawn Thu, 14 Feb 2008 12:00:00 EST Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of TamoxifenCondition: Breast CancerInterventions: Drug: exemestane; Drug: Placebo Sponsors: NSABP Foundation Inc; National Cancer Institute (NCI) Completed Mon, 27 Jan 2003 12:00:00 EST 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast CancerCondition: Metastatic Breast CancerInterventions: Drug: Exemestane; Drug: Everolimus (RAD001) Sponsor: Novartis Pharmaceuticals Completed Fri, 22 Jun 2012 12:00:00 EDT Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast CancerCondition: Breast CancerInterventions: Drug: ribociclib (LEE011); Drug: Exemestane; Drug: Everolimus (RAD001) Sponsor: Novartis Pharmaceuticals Completed Mon, 20 May 2013 12:00:00 EDT
1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast CancerCondition: First Line Metastatic Breast CancerInterventions: Drug: Paclitaxel; Drug: Bevacizumab; Drug: Exemestane Sponsor: ARCAGY/ GINECO GROUP Terminated Fri, 25 Feb 2011 12:00:00 EST A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBCCondition: Metastatic Breast CancerInterventions: Drug: Palbociclib; Drug: Exemestane; Drug: Leuprolide Acetate; Drug: Capecitabine Sponsor: Samsung Medical Center Unknown status Fri, 30 Oct 2015 12:00:00 EDT Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung CancerCondition: Stage IV Non-small Cell Lung CancerInterventions: Drug: exemestane; Drug: pemetrexed disodium; Drug: carboplatin; Other: laboratory biomarker analysis; Other: pharmacological study; Other: questionnaire administration; Procedure: quality-of-life assessment Sponsors: Jonsson Comprehensive Cancer Center; National Cancer Institute (NCI) Completed Tue, 14 Aug 2012 12:00:00 EDT A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole TherapyConditions: Metastatic ER+ Her2- Breast Cancer; PostmenopausalInterventions: Drug: Exemestane; Drug: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane; Drug: Abiraterone acetate + Prednisone or Prednisolone Sponsor: Janssen Research & Development, LLC Completed Mon, 27 Jun 2011 12:00:00 EDT Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast CancerCondition: Breast NeoplasmsInterventions: Drug: CP-751,871; Drug: exemestane; Drug: Fulvestrant Sponsor: Pfizer Terminated Thu, 07 Sep 2006 12:00:00 EDT Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast CancerCondition: Breast CancerInterventions: Drug: Sapanisertib; Drug: Fulvestrant; Drug: Exemestane Sponsor: Millennium Pharmaceuticals, Inc. Completed Thu, 30 Jan 2014 12:00:00 EST Study of KHK2375 in Subjects With Advanced or Recurrent Breast CancerCondition: Breast CancerInterventions: Drug: KHK2375; Drug: Exemestane Sponsor: Kyowa Kirin Co., Ltd. Active, not recruiting Tue, 08 Dec 2015 12:00:00 EST Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast CancerCondition: Breast NeoplasmsInterventions: Drug: Tamoxifen; Drug: Exemestane Sponsors: Pfizer; International Collaborative Cancer Group Completed Mon, 03 Jun 2002 12:00:00 EDT A Study of LXI-15029 in Patients With Advanced Malignant Solid TumorsCondition: Advanced Breast CancerInterventions: Drug: LXI-15029; Drug: LXI-15029+Exemestane Sponsor: Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. Recruiting Mon, 24 Apr 2017 12:00:00 EDT Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.Condition: Breast CancerInterventions: Drug: Ribociclib; Drug: Everolimus; Drug: Exemestane Sponsor: Novartis Pharmaceuticals Completed Fri, 08 Apr 2016 12:00:00 EDT
Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast CancerCondition: Breast CancerInterventions: Drug: anastrozole; Drug: letrozole; Drug: exemestane Sponsor: Fudan University Unknown status Fri, 15 May 2009 12:00:00 EDT Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast CancerConditions: Estrogen Receptor-positive Breast Cancer; Progesterone Receptor Positive Tumor; Recurrent Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast CancerInterventions: Biological: therapeutic estradiol; Drug: exemestane; Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay Sponsors: University of Arizona; National Cancer Institute (NCI) Completed Thu, 30 Jun 2011 12:00:00 EDT Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast CancerCondition: Breast CancerInterventions: Drug: exemestane; Drug: sunitinib malate; Other: placebo Sponsor: Institut Català d'Oncologia Unknown status Thu, 02 Jul 2009 12:00:00 EDT The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has SpreadCondition: Breast NeoplasmsInterventions: Drug: Xentuzumab; Drug: Placebo; Drug: Everolimus; Drug: Exemestane Sponsor: Boehringer Ingelheim Active, not recruiting Thu, 06 Sep 2018 12:00:00 EDT A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）Condition: CYP2D6 PolymorphismInterventions: Drug: Exemestane Tablets; Other: ovarian function suppression/ablation; Genetic: CYP2D6*10 gene test; Drug: Tamoxifen Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Pfizer Enrolling by invitation Tue, 02 May 2017 12:00:00 EDT BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid TumorsCondition: NeoplasmsInterventions: Drug: BI 860585; Drug: exemestane; Drug: paclitaxel Sponsor: Boehringer Ingelheim Completed Tue, 10 Sep 2013 12:00:00 EDT ELBA: Exemestane and Lapatinib in Advanced Breast CancerCondition: Breast CancerInterventions: Drug: exemestane; Drug: lapatinib Sponsor: National Cancer Institute, Naples Withdrawn Sun, 01 Nov 2009 12:00:00 EDT Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast CancerCondition: Breast CancerInterventions: Drug: exemestane; Drug: goserelin acetate Sponsors: NYU Langone Health; National Cancer Institute (NCI) Completed Wed, 21 Apr 2004 12:00:00 EDT 500mg Fulvestrant Versus Exemestane in MBCCondition: Breast CancerIntervention: Sponsor: Fudan University Completed Mon, 02 Jul 2018 12:00:00 EDT QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast CancerConditions: Breast Cancer; Breast Tumors; Metastatic CancerIntervention: Drug: AMG 479 or placebo administered with either exemestane or fulvestrant Sponsor: NantCell, Inc. Completed Fri, 29 Feb 2008 12:00:00 EST
Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast CancerCondition: Breast CancerInterventions: Drug: exemestane; Drug: tamoxifen citrate Sponsors: International Collaborative Cancer Group; European Organisation for Research and Treatment of Cancer - EORTC; UNICANCER Unknown status Fri, 23 Jan 2004 12:00:00 EST Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast CancerCondition: Breast CancerInterventions: Drug: exemestane; Drug: tamoxifen citrate Sponsor: European Organisation for Research and Treatment of Cancer - EORTC Completed Fri, 11 Apr 2003 12:00:00 EDT PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast CancerCondition: Metastatic Breast CancerInterventions: Drug: Palbociclib; Drug: Exemestane; Drug: Goserelin Sponsor: Hamdy A. Azim Recruiting Wed, 28 Sep 2016 12:00:00 EDT Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast CancerCondition: Breast CancerInterventions: Biological: trastuzumab; Drug: exemestane Sponsors: Northwestern University; National Cancer Institute (NCI) Withdrawn Wed, 09 Apr 2003 12:00:00 EDT Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer PatientsCondition: Breast CancerInterventions: Drug: OFS + Anastrozole; Drug: OFS + Exemestane Sponsor: Shanghai Jiao Tong University School of Medicine Recruiting Tue, 12 May 2015 12:00:00 EDT Ruxolitinib in Estrogen Receptor Positive Breast CancerCondition: Estrogen-receptor Positive Invasive Metastatic Breast CancerInterventions: Drug: Ruxolitinib; Drug: Exemestane Sponsor: Abramson Cancer Center of the University of Pennsylvania Completed Wed, 09 May 2012 12:00:00 EDT Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer PatientsCondition: Male Breast CancerInterventions: Drug: Tamoxifen; Drug: Tamoxifen and GnRH analogue; Drug: Exemestane and GnRH analogue Sponsors: German Breast Group; Pfizer Completed Wed, 11 Jul 2012 12:00:00 EDT Metabolizing Enzyme Genotype Versus Exemestane Metabolism ProfilesCondition: Breast CancerIntervention: Sponsor: Milton S. Hershey Medical Center Completed Fri, 22 Jun 2012 12:00:00 EDT Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast CancerCondition: Breast CancerInterventions: Drug: Entinostat; Drug: Exemestane Sponsor: Taizhou EOC Pharma Co., Ltd. Completed Thu, 14 Jul 2016 12:00:00 EDT Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase InhibitorsCondition: Metastatic Breast CancerInterventions: Drug: Palbociclib; Drug: Capecitabine; Drug: Exemestane; Drug: Fulvestrant Sponsors: Spanish Breast Cancer Research Group; Pfizer; AstraZeneca Completed Tue, 07 Jan 2014 12:00:00 EST
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or MetastaticConditions: Breast Adenocarcinoma; HER2/Neu Negative; Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7Interventions: Drug: Entinostat; Drug: Exemestane; Drug: Goserelin; Drug: Goserelin Acetate; Other: Placebo Administration; Other: Quality-of-Life Assessment Sponsor: National Cancer Institute (NCI) Active, not recruiting Wed, 16 Apr 2014 12:00:00 EDT Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast CancerConditions: Estrogen Receptor Positive Breast Cancer; Progesterone Receptor Positive Tumor; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast CancerInterventions: Drug: Exemestane; Other: Laboratory Biomarker Analysis; Procedure: Oophorectomy; Other: Quality-of-Life Assessment; Radiation: Radiation Therapy; Drug: Tamoxifen; Drug: Triptorelin Sponsors: International Breast Cancer Study Group; Breast International Group; Cancer and Leukemia Group B; National Cancer Institute (NCI); NSABP Foundation Inc; NCIC Clinical Trials Group; North Central Cancer Treatment Group; Southwest Oncology Group Active, not recruiting Thu, 07 Aug 2003 12:00:00 EDT A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast CancerCondition: Breast NeoplasmsInterventions: Drug: E7090; Drug: Fulvestrant; Drug: Exemestane Sponsor: Eisai Co., Ltd. Recruiting Thu, 01 Oct 2020 12:00:00 EDT Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast CancerCondition: Breast CancerInterventions: Drug: exemestane; Drug: tamoxifen citrate; Procedure: adjuvant therapy Sponsor: Cancer Research Campaign Clinical Trials Centre Completed Mon, 27 Jan 2003 12:00:00 EST Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With BevacizumabConditions: Breast Cancer Recurrent; HER2/Neu-negative Carcinoma of Breast; Hormone Receptor Positive Malignant Neoplasm of BreastInterventions: Drug: Bevacizumab; Drug: Capecitabine; Drug: Everolimus; Drug: Exemestane; Other: Patient questionaires Sponsors: iOMEDICO AG; Arbeitsgemeinschaft fur Internistische Onkologie; Novartis Pharmaceuticals Completed Thu, 25 Sep 2014 12:00:00 EDT Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast CancerCondition: Metastatic Breast CancerInterventions: Drug: Enobosarm & Abemaciclib Combo; Drug: non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant Sponsor: Veru Inc. Not yet recruiting Mon, 04 Oct 2021 12:00:00 EDT MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast CancerCondition: Metastatic Breast CancerInterventions: Drug: MSK-2206; Drug: Exemestane; Drug: Goserelin Sponsor: Vanderbilt-Ingram Cancer Center Withdrawn Mon, 15 Nov 2010 12:00:00 EST Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast CancerCondition: Breast CancerInterventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole; Procedure: Therapeutic Conventional Surgery Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Cancer and Leukemia Group B Completed Thu, 15 Dec 2005 12:00:00 EST Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast CancerCondition: Metastatic Breast CancerInterventions: Drug: Enobosarm; Drug: Exemestane Sponsor: Veru Inc. Recruiting Mon, 03 May 2021 12:00:00 EDT Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast CancerCondition: Advanced or Recurrent Breast CancerInterventions: Drug: Entinostat; Drug: Entinostat(Placebo); Drug: Exemestane Sponsor: Kyowa Kirin Co., Ltd. Active, not recruiting Mon, 25 Sep 2017 12:00:00 EDT
Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast CancerCondition: Hormone Receptor Positive Breast CancerInterventions: Drug: Everolimus; Drug: Letrozole; Drug: Exemestane; Drug: Alcohol-free dexamethasone mouth rinse Sponsor: Novartis Pharmaceuticals Completed Wed, 03 Oct 2012 12:00:00 EDT Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast CancerCondition: Breast CancerInterventions: Drug: anastrozole; Drug: exemestane; Drug: fulvestrant Sponsor: Institute of Cancer Research, United Kingdom Unknown status Tue, 15 Nov 2005 12:00:00 EST Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By SurgeryCondition: Breast CancerInterventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate Sponsor: Gruppo Italiano Mammella (GIM) Active, not recruiting Mon, 08 Oct 2007 12:00:00 EDT Pharmacology of Adjuvant Hormonotherapy in Breast CancerCondition: Hormono-depending Adjuvant Breast CancerIntervention: Drug: Tamoxifen, Letrozole, Anastrozole or Exemestane Sponsor: Institut Claudius Regaud Completed Thu, 20 May 2010 12:00:00 EDT BI 836845 in Estrogen Receptor Positive Metastatic Breast CancerCondition: NeoplasmsInterventions: Drug: Everolimus; Drug: Exemestane; Drug: BI 836845 Sponsor: Boehringer Ingelheim Active, not recruiting Mon, 28 Apr 2014 12:00:00 EDT Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer PatientsConditions: Breast Cancer; Pain; ArthralgiaInterventions: Drug: Anastrozole; Drug: exemestane; Drug: letrozole Sponsors: Lynn Henry; Damon Runyon Cancer Research Foundation Completed Tue, 19 Mar 2013 12:00:00 EDT 500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AICondition: Breast CancerIntervention: Sponsor: Fudan University Completed Thu, 04 Oct 2018 12:00:00 EDT Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast CancerCondition: Breast CancerIntervention: Drug: Tamoxifen, Letrozole , Anastrozole, Exemestane Sponsor: Institut Claudius Regaud Completed Wed, 06 Jun 2012 12:00:00 EDT Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast CancerConditions: Breast Cancer; Arthralgia; ObesityInterventions: Drug: anastrozole, letrozole, exemestane; Drug: Tamoxifen Sponsor: University of Michigan Rogel Cancer Center Completed Thu, 11 Jul 2013 12:00:00 EDT Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast CancerCondition: Breast CancerInterventions: Drug: SOD1 inhibitor ATN-224; Drug: exemestane; Genetic: protein expression analysis; Genetic: proteomic profiling; Other: laboratory biomarker analysis; Other: pharmacological study Sponsor: Cancer Research UK Terminated Thu, 08 May 2008 12:00:00 EDT
Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02Conditions: Breast Cancer; Fatigue; Sleep DisordersInterventions: Drug: Tamoxifen; Drug: triptorelin; Drug: Exemestane Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Breast Cancer Trials, Australia and New Zealand; Cancer and Leukemia Group B Completed Wed, 16 Apr 2008 12:00:00 EDT CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast CancerCondition: Breast CancerIntervention: Drug: Anastrozole or Letrozole or Exemestane Sponsors: IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy; Clinical Research Technology S.r.l. Recruiting Wed, 28 Sep 2016 12:00:00 EDT Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast CancerConditions: Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast CancerInterventions: Drug: exemestane; Procedure: adjuvant therapy; Procedure: aromatase inhibition; Procedure: conventional surgery; Procedure: endocrine therapy; Procedure: hormone therapy; Procedure: neoadjuvant therapy; Procedure: surgery Sponsors: Robert H. Lurie Cancer Center; National Cancer Institute (NCI) Withdrawn Thu, 08 Apr 2004 12:00:00 EDT A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)Condition: Breast CancerInterventions: Drug: ridaforolimus + dalotuzumab; Drug: exemestane; Drug: ridaforolimus; Drug: dalotuzumab Sponsor: Merck Sharp & Dohme Corp. Completed Thu, 04 Nov 2010 12:00:00 EDT Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast CancerCondition: Advanced Breast CancerInterventions: Drug: Dexamethasone based mouthwash; Drug: Everolimus; Drug: Exemestane Sponsor: Novartis Pharmaceuticals Completed Fri, 21 Feb 2014 12:00:00 EST Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast CancerCondition: Breast CancerInterventions: Drug: Hemay022+exemestane; Drug: Hemay022+letrozole; Drug: Hemay022+ fulvestrant Sponsor: Tianjin Hemay Pharmaceutical Co.,Ltd Recruiting Thu, 12 Oct 2017 12:00:00 EDT The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast CancerCondition: Breast CancerInterventions: Drug: Tamoxifen Citrate; Drug: Letrozole; Drug: Exemestane; Diagnostic Test: Blueprint; Diagnostic Test: Mammaprint Sponsors: Johns Hopkins University; Agendia Recruiting Wed, 16 Oct 2019 12:00:00 EDT Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast CancerConditions: Breast Ductal Carcinoma In Situ; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast CarcinomaInterventions: Drug: Anastrozole; Drug: Exemestane; Other: Laboratory Biomarker Analysis; Drug: Letrozole; Other: Quality-of-Life Assessment; Drug: Systemic Chemotherapy; Drug: Tamoxifen Citrate Sponsor: National Cancer Institute (NCI) Active, not recruiting Fri, 07 Jan 2011 12:00:00 EST De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)Condition: Stage I Breast CancerInterventions: Other: Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane); Drug: Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane) Sponsors: NRG Oncology; National Cancer Institute (NCI) Not yet recruiting Wed, 21 Apr 2021 12:00:00 EDT Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and ExemestaneCondition: Metastatic Breast CancerInterventions: Drug: Everolimus; Drug: Everolimus-placebo Sponsors: German Breast Group; Novartis Terminated Wed, 23 Jan 2013 12:00:00 EST
Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast CancerCondition: Breast CancerInterventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate Sponsor: Centre Oscar Lambret Unknown status Tue, 05 May 2009 12:00:00 EDT Effects of Exemestane on Bone StrengthConditions: Osteoporosis; Breast CancerIntervention: Sponsors: University Health Network, Toronto; Canadian Breast Cancer Research Alliance Unknown status Tue, 15 Jun 2010 12:00:00 EDT Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer PatientsConditions: FGFR Inhibition, Pharmacokinetics, Biomarkers; ER+ Breast CancerInterventions: Drug: AZD4547; Drug: Exemestane; Drug: Placebo; Drug: Fulvestrant Sponsor: AstraZeneca Completed Thu, 16 Sep 2010 12:00:00 EDT Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung CancerConditions: Lung Cancer; Non Small Cell Lung Cancer (NSCLC); Breast Cancer; Estrogen Receptor Breast CancerInterventions: Drug: entinostat; Drug: Erlotinib; Drug: Exemestane Sponsor: Syndax Pharmaceuticals Completed Wed, 09 May 2012 12:00:00 EDT Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast CancerCondition: Breast CancerInterventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole; Drug: sorafenib tosylate; Other: placebo Sponsors: Mayo Clinic; National Cancer Institute (NCI) Terminated Fri, 14 Dec 2007 12:00:00 EST Neoadjuvant Endocrine Therapy Tolerance in Geriatric Early Stage ER+ Breast CancerCondition: Breast Cancer FemaleInterventions: Drug: tamoxifen, letrozole, anastrozole, or exemestane; Behavioral: Patient reported outcomes Sponsor: Trish Millard, MD Recruiting Mon, 17 Feb 2020 12:00:00 EST A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast CancerConditions: Postmenopause; Breast CancerIntervention: Sponsor: AstraZeneca Completed Wed, 28 Jul 2010 12:00:00 EDT Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast CancerCondition: Breast CancerInterventions: Drug: enzalutamide; Drug: anastrozole; Drug: exemestane; Drug: fulvestrant Sponsors: Pfizer; Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc. Completed Fri, 11 May 2012 12:00:00 EDT Study of LY3484356 Versus Hormone Therapy, in Participants With Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast CancerConditions: Breast Neoplasms; Neoplasm MetastasisInterventions: Drug: LY3484356; Drug: Exemestane; Drug: Fulvestrant Sponsor: Eli Lilly and Company Not yet recruiting Fri, 23 Jul 2021 12:00:00 EDT PAlbociclib and Circulating Tumor DNA for ESR1 Mutation DetectionCondition: Metastatic Breast CancerInterventions: Drug: Palbociclib 125mg; Drug: Aromatase Inhibitors; Drug: Fulvestrant Injectable Product Sponsors: UNICANCER; Pfizer Active, not recruiting Tue, 14 Mar 2017 12:00:00 EDT
Premenopausal Endocrine Responsive Chemotherapy TrialCondition: Breast CancerInterventions: Drug: chemotherapy; Drug: exemestane; Drug: tamoxifen; Drug: triptorelin; Procedure: oophorectomy; Procedure: ovarian irradiation Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Breast International Group Terminated Thu, 07 Aug 2003 12:00:00 EDT Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast CancerCondition: Breast CancerInterventions: Drug: Elacestrant; Drug: Standard of Care Sponsor: Radius Pharmaceuticals, Inc. Active, not recruiting Wed, 19 Dec 2018 12:00:00 EST Aromatase Inhibitor and Durvalumab in Postmenopausal Breast CancerConditions: Breast Cancer; Hormone Receptor Positive TumorInterventions: Drug: Durvalumab; Drug: Anastrozole 1mg; Drug: Letrozole 2.5mg; Drug: Exemestane 25 MG Sponsors: H. Lee Moffitt Cancer Center and Research Institute; AstraZeneca Active, not recruiting Thu, 14 Mar 2019 12:00:00 EDT Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR InhibitorCondition: Metastatic Breast CancerIntervention: Procedure: Biopsy Sponsors: UNICANCER; Novartis; Fondation ARC Active, not recruiting Thu, 14 May 2015 12:00:00 EDT Effects of Adjuvant Endocrine Therapy With Aromatase Inhibitors on the Postoperative Lipid Levels in Postmenopausal Breast Cancer PatientsCondition: Breast CancerInterventions: Drug: Exemestane; Drug: Letrozole; Drug: Anastrozole Sponsor: Chinese Academy of Medical Sciences Unknown status Fri, 06 May 2016 12:00:00 EDT Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer PatientsCondition: Breast Cancer MetastaticInterventions: Drug: Everolimus; Drug: Aromatase Inhibitors Sponsors: Istituto Oncologico Veneto IRCCS; University of Padova Completed Thu, 30 Jul 2015 12:00:00 EDT Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or FulvestrantConditions: Breast Cancer; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of BreastInterventions: Drug: Palbociclib; Drug: Letrozole; Drug: Anastrozole; Drug: Exemestane; Drug: Fulvestrant Sponsors: iOMEDICO AG; Pfizer Active, not recruiting Fri, 09 Sep 2016 12:00:00 EDT Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02Conditions: Breast Cancer; OsteoporosisInterventions: Other: laboratory biomarker analysis; Procedure: dual x-ray absorptiometry Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Breast International Group Active, not recruiting Fri, 21 Aug 2009 12:00:00 EDT Study of Estrogen Levels in Premenopausal Women Who Have Undergone Surgery for Breast Cancer and Are Receiving Triptorelin and Tamoxifen Citrate or Exemestane on Clinical Trial IBCSG 24-02Condition: Breast CancerIntervention: Other: gas chromatography / tandem mass spectometry Sponsor: International Breast Cancer Study Group Completed Fri, 11 Sep 2009 12:00:00 EDT ExclUsive endocRine Therapy Or Partial Breast Irradiation for Women Aged ≥70 Years Early Stage Breast CancerCondition: Breast CancerInterventions: Radiation: Partial Breast Irradiation (PBI); Drug: Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen Sponsors: Azienda Ospedaliero-Universitaria Careggi; University of Florence Recruiting Tue, 22 Oct 2019 12:00:00 EDT
Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast CancerCondition: Breast CancerInterventions: Drug: Capecitabine; Drug: Aromatase Inhibitor Sponsor: Sun Yat-sen University Recruiting Tue, 10 May 2016 12:00:00 EDT Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast CancerConditions: Breast Cancer; Invasive Breast CancerInterventions: Drug: Anastrozole; Drug: Letrozole; Drug: Exemestane; Drug: Tamoxifen Sponsor: Medical College of Wisconsin Active, not recruiting Mon, 17 Jul 2017 12:00:00 EDT Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast CancerCondition: Breast CancerInterventions: Drug: capecitabine; Drug: hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole) Sponsor: The Netherlands Cancer Institute Terminated Mon, 26 May 2008 12:00:00 EDT Bone Mineral Density in Postmenopausal Women at Increased Risk of Breast Cancer And Who Are Receiving Exemestane on MAP3Conditions: Breast Cancer; OsteoporosisInterventions: Other: biologic sample preservation procedure; Procedure: dual x-ray absorptometry Sponsor: NCIC Clinical Trials Group Completed Mon, 02 Jun 2008 12:00:00 EDT Relationship Between Body Composition, Food Consumption, and Micro and Macronutrients With Gene Expression in Breast CancerConditions: Breast Cancer; Endocrine Therapy; Endocrine Therapy Adverse Reaction; Vitamin D Deficiency; Nutrition Disorders; ObesityInterventions: Drug: Tamoxifen; Drug: Exemestane; Drug: Anastrozole; Diagnostic Test: Basal; Diagnostic Test: Recurrence Sponsors: Instituto Jalisciense de Cancerologia; University of Guadalajara Recruiting Fri, 15 May 2020 12:00:00 EDT Aromatase Inhibitor Clinical TrialCondition: Breast CancerIntervention: Drug: pharmacodynamic analysis Sponsors: National Institute of General Medical Sciences (NIGMS); Indiana University School of Medicine; Office of Research on Women's Health (ORWH); National Institute of Environmental Health Sciences (NIEHS) Unknown status Thu, 29 Sep 2005 12:00:00 EDT Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast CancerCondition: Breast CancerIntervention: Procedure: quality-of-life assessment Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); NCIC Clinical Trials Group Completed Wed, 08 Sep 2004 12:00:00 EDT Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast CancerCondition: Metastatic Breast CancerInterventions: Drug: AI plus Dimethyldiguanide; Drug: Aromatase Inhibitor Sponsor: Xichun Hu Completed Tue, 31 Jul 2012 12:00:00 EDT Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted TherapyCondition: HR+ HER2- Men, Pre/Postmenopausal Advanced Breast CancerInterventions: Drug: Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant; Drug: Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy Sponsor: Novartis Pharmaceuticals Active, not recruiting Thu, 28 Apr 2016 12:00:00 EDT Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)Condition: Low Grade Endometrial Stromal SarcomaIntervention: Drug: Aromatase Inhibitors Sponsor: Centre Leon Berard Recruiting Fri, 10 Aug 2018 12:00:00 EDT
Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast CancerCondition: Metastatic Breast CancerInterventions: Drug: MK-2206; Drug: Exemestane; Drug: Goserelin Sponsor: Vanderbilt-Ingram Cancer Center Withdrawn Mon, 15 Nov 2010 12:00:00 EST Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or NotCondition: Breast CancerInterventions: Drug: Tamoxifen,; Drug: Exemestane; Drug: Anastrozole; Drug: Letrozole Sponsor: Institut Claudius Regaud Completed Wed, 14 Mar 2012 12:00:00 EDT A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).Condition: Metastatic Breast CancerIntervention: Drug: Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen) Sponsors: German Breast Group; Pfizer; AMS Advanced Medical Services GmbH Recruiting Tue, 28 Nov 2017 12:00:00 EST Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast CancerCondition: Breast NeoplasmsIntervention: Drug: Endocrine therapy Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting Wed, 17 Jul 2019 12:00:00 EDT Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence ScoreConditions: Breast Cancer; Cancer of Breast; Breast Neoplasms; Cancer of the BreastInterventions: Behavioral: FACT-B; Drug: Goserelin; Drug: Anastrozole; Drug: Exemestane; Drug: Fulvestrant; Drug: Tamoxifen; Other: Archived tissue collection Sponsors: Washington University School of Medicine; Genomic Health®, Inc. Recruiting Fri, 19 Jun 2015 12:00:00 EDT Dendritic Cell Based Therapy for Breast Cancer PatientsCondition: Breast CancerInterventions: Biological: DC vaccine; Drug: aromatase inhibitor Sponsor: Inge Marie Svane Withdrawn Thu, 09 Jul 2009 12:00:00 EDT Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast CancerCondition: Breast CancerInterventions: Genetic: polymorphism analysis; Other: high performance liquid chromatography; Other: laboratory biomarker analysis; Procedure: radiomammography Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Completed Wed, 15 Aug 2007 12:00:00 EDT Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer PatientsCondition: Breast CancerInterventions: Drug: Aromatase Inhibitors (Arimidex); Drug: Tamoxifen; Procedure: SOB; Drug: FAC; Drug: Aromatase Inhibitors (Femara); Drug: Aromatase Inhibitors (Aromasin) Sponsor: Dharmais National Cancer Center Hospital Completed Fri, 16 Dec 2016 12:00:00 EST Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the BreastCondition: Breast CancerInterventions: Drug: Tamoxifen; Drug: Toremifene; Drug: Anastrozole; Drug: Letrozole; Drug: Exemestane Sponsors: First Hospital of China Medical University; The First Hospital of Jilin University; Second Hospital of Jilin University; Jilin Provincial Tumor Hospital; The Affiliated Zhongshan Hospital of Dalian University; The First Affiliated Hospital of Dalian Medical University; China-Japan Union Hospital, Jilin University; The Second Affiliated Hospital of Dalian Medical University; The Fifth People's Hospital of Shenyang; General Hospital of Benxi Steel & Iron (Group) Co., Ltd; Affiliated Hospital of Hebei University of Engineering; Fourth People's Hospital of Shenyang Active, not recruiting Mon, 14 Dec 2020 12:00:00 EST Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast CancerCondition: Breast Cancer MetastaticInterventions: Drug: Amcenestrant; Drug: Fulvestrant; Drug: Anastrozole; Drug: Letrozole; Drug: Exemestane; Drug: Tamoxifen Sponsor: Sanofi Recruiting Fri, 16 Aug 2019 12:00:00 EDT
Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer PatientsCondition: Breast CancerInterventions: Drug: Epirubicin; Drug: Cyclophosphamide; Drug: Triptorelin; Drug: Exemestane; Drug: Nivolumab Sponsors: Istituto Oncologico Veneto IRCCS; University of Padova Completed Wed, 09 Dec 2020 12:00:00 EST Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast CancerCondition: Breast CancerInterventions: Drug: Bicalutamide; Drug: Aromatase Inhibitor Sponsors: Xu fei; Sun Yat-sen University Unknown status Wed, 21 Sep 2016 12:00:00 EDT NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast CancerCondition: Breast NeoplasmsInterventions: Drug: Exemestane; Drug: Letrozole; Drug: Anastrozole; Drug: Leuprolide Acetate; Drug: Pertuzumab; Drug: Trastuzumab Sponsor: Midwestern Regional Medical Center Unknown status Wed, 24 Feb 2016 12:00:00 EST Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast CancerConditions: Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Negative; Progesterone Receptor Positive; Stage IV Breast Cancer; Triple-Negative Breast CarcinomaInterventions: Drug: Anastrozole; Drug: Doxorubicin Hydrochloride; Drug: Exemestane; Other: Laboratory Biomarker Analysis; Drug: Letrozole; Biological: Pembrolizumab Sponsors: City of Hope Medical Center; National Cancer Institute (NCI); Merck Sharp & Dohme Corp. Active, not recruiting Thu, 07 Jan 2016 12:00:00 EST ER Reactivation Therapy for Breast CancerCondition: Metastatic Breast CancerInterventions: Drug: 17B-estradiol; Drug: Letrozole; Drug: Anastrozole; Drug: Exemestane Sponsor: Dartmouth-Hitchcock Medical Center Recruiting Mon, 14 Jul 2014 12:00:00 EDT Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast CancerCondition: Breast Cancer MetastaticInterventions: Drug: Ribociclib; Drug: Anastrozole; Drug: Letrozole; Drug: Exemestane; Drug: Fulvestrant Sponsor: German Breast Group Recruiting Thu, 14 Jun 2018 12:00:00 EDT Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor TherapyConditions: Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast CancerInterventions: Drug: vorinostat; Other: laboratory biomarker analysis; Procedure: biopsy; Radiation: F-18 16 alpha-fluoroestradiol; Procedure: positron emission tomography; Drug: anastrozole; Drug: letrozole; Drug: exemestane; Genetic: gene expression analysis Sponsors: University of Washington; National Cancer Institute (NCI) Completed Wed, 30 Jun 2010 12:00:00 EDT Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast CancerConditions: HER2/Neu Negative; Invasive Breast Carcinoma; Postmenopausal; Stage 0 Breast Cancer; Stage IA Breast CancerInterventions: Drug: Anastrozole; Drug: Exemestane; Other: Laboratory Biomarker Analysis; Drug: Letrozole; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Drug: Tamoxifen Citrate; Drug: Toremifene Citrate Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI) Withdrawn Thu, 03 Aug 2017 12:00:00 EDT To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine TherapyCondition: Breast CancerInterventions: Drug: Palbociclib; Drug: Anastrozole; Drug: Letrozole; Drug: Exemestane; Drug: Fulvestrant Sponsor: Fondazione Sandro Pitigliani Completed Tue, 15 Sep 2015 12:00:00 EDT Breast Cancer, Sexuality and Black CohoshCondition: SexualityInterventions: Behavioral: WHOQOL questionnaire; Behavioral: FSFI questionnaire; Behavioral: kupperman scale; Drug: Cimicifuga racemosa; Drug: tamoxifen; Drug: exemestane Sponsor: Irmandade da Santa Casa de Misericordia de Sao Paulo Unknown status Wed, 10 Jun 2015 12:00:00 EDT
Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone MetastasisConditions: Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Metastatic Breast Carcinoma; Metastatic Malignant Neoplasm in the Bone; Progesterone Receptor Positive; Prognostic Stage IV Breast Cancer AJCC v8Interventions: Drug: Anastrozole; Drug: Exemestane; Drug: Fulvestrant; Drug: Letrozole; Drug: Palbociclib; Radiation: Radiation Therapy; Drug: Tamoxifen Sponsors: Emory University; Pfizer Recruiting Mon, 01 Oct 2018 12:00:00 EDT Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.Condition: Metastatic Breast CancerInterventions: Drug: Avastin; Drug: Hormonal therapy Sponsors: University of Alabama at Birmingham; Genentech, Inc. Completed Mon, 17 Oct 2005 12:00:00 EDT Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone TherapyConditions: Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast CancerInterventions: Drug: vorinostat; Drug: anastrozole; Drug: letrozole; Drug: exemestane; Procedure: positron emission tomography; Radiation: F-18 16 alpha-fluoroestradiol; Radiation: fludeoxyglucose F 18; Other: laboratory biomarker analysis Sponsors: University of Washington; National Cancer Institute (NCI) Completed Fri, 02 Nov 2012 12:00:00 EDT Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast CancerCondition: Metastatic Breast CancerInterventions: Drug: Paclitaxel; Drug: Bevacizumab; Drug: Letrozole; Drug: Anastrozole; Drug: Exemestane; Drug: Fulvestrant; Drug: Goserelin; Drug: leuprorelin; Drug: LHRH Analogs + Aromatase inhibitors Sponsors: Japan Breast Cancer Research Group; Chugai Pharmaceutical Unknown status Thu, 21 Nov 2013 12:00:00 EST Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast CancerCondition: Breast CancerInterventions: Drug: Dovitinib; Drug: Aromatase Inhibitors Sponsors: Georgetown University; Novartis Pharmaceuticals Terminated Fri, 02 Dec 2011 12:00:00 EST Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast CancerConditions: Breast Cancer Female; HER2-positive Breast Cancer; Hormone Receptor Positive Malignant Neoplasm of Breast; Metastatic Breast Cancer; Breast Diseases; Hormone Receptor Positive TumorInterventions: Drug: Pyrotinib; Drug: Trastuzumab; Drug: Aromatase Inhibitors Sponsor: Fuzhou General Hospital Not yet recruiting Thu, 12 Sep 2019 12:00:00 EDT Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBCConditions: Breast Cancer Female; HER2-positive Breast Cancer; Hormone Receptor Positive Malignant Neoplasm of Breast; Metastatic Breast Cancer; Breast Diseases; Hormone Receptor Positive TumorInterventions: Drug: Pyrotinib; Drug: Trastuzumab; Drug: Aromatase inhibitor Sponsor: Peking Union Medical College Hospital Not yet recruiting Wed, 10 Apr 2019 12:00:00 EDT A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast CancerCondition: Breast NeoplasmInterventions: Drug: Megestrol Acetate 160Mg Tablet; Drug: Anastrozole 1Mg Tablet; Drug: Letrozole 2.5Mg Tablet; Drug: Exemestane 25 MG; Drug: Tamoxifen 20Mg Tablet; Drug: Fulvestrant 50Mg Solution for Injection Sponsors: Instituto Nacional de Cancer, Brazil; Cancer Research UK Cambridge Institute Unknown status Thu, 19 Jan 2017 12:00:00 EST Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)Conditions: Breast Adenocarcinoma; Hormone Receptor Positive; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIB Breast Cancer AJCC v7Interventions: Drug: Anastrozole; Drug: Exemestane; Other: Laboratory Biomarker Analysis; Drug: Letrozole; Other: Quality-of-Life Assessment; Radiation: Radiation Therapy; Drug: Tamoxifen Citrate Sponsors: National Cancer Institute (NCI); American College of Surgeons; Cancer and Leukemia Group B; NSABP Foundation Inc; NCIC Clinical Trials Group; North Central Cancer Treatment Group; Southwest Oncology Group Active, not recruiting Mon, 03 Apr 2006 12:00:00 EDT Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast CancerCondition: Breast CancerInterventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole; Procedure: assessment of therapy complications Sponsors: Mayo Clinic; National Cancer Institute (NCI) Active, not recruiting Tue, 22 Jul 2008 12:00:00 EDT
Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast CancerCondition: Breast CancerIntervention: Drug: Neratinib + endocrine therapy Sponsor: SOLTI Breast Cancer Research Group Recruiting Tue, 07 Jul 2020 12:00:00 EDT S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast CancerCondition: Breast CancerInterventions: Drug: anastrozole; Drug: everolimus; Drug: exemestane; Drug: goserelin acetate; Drug: letrozole; Drug: leuprolide acetate; Drug: tamoxifen citrate; Other: placebo Sponsors: Southwest Oncology Group; National Cancer Institute (NCI) Active, not recruiting Tue, 28 Aug 2012 12:00:00 EDT T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With Metastatic, Unresectable, or Locoregionally Recurrent HER2- Negative Breast CancerConditions: Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Recurrent Breast CarcinomaInterventions: Drug: Anastrozole; Drug: Exemestane; Drug: Fulvestrant; Drug: Letrozole; Drug: Paclitaxel; Biological: Talimogene Laherparepvec; Drug: Tamoxifen; Drug: Nab paclitaxel; Drug: Gemcitabine; Drug: Carboplatin Sponsors: University of California, San Francisco; Amgen Recruiting Tue, 12 Jun 2018 12:00:00 EDT Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled StudyCondition: Metastatic Breast CancerInterventions: Drug: Capecitabine plus aromatase inhibitor; Drug: A.I. Sponsor: Ain Shams University Unknown status Tue, 09 Jul 2019 12:00:00 EDT FASN Inhibitor TVB-2640 and Trastuzumab in Combination With Paclitaxel or Endocrine Therapy for the Treatment of HER2 Positive Metastatic Breast CancerConditions: Advanced Breast Carcinoma; HER2 Positive Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7Interventions: Drug: Anastrozole; Drug: Exemestane; Drug: FASN Inhibitor TVB-2640; Drug: Fulvestrant; Other: Laboratory Biomarker Analysis; Drug: Letrozole; Drug: Paclitaxel; Biological: Trastuzumab Sponsors: Mayo Clinic; National Cancer Institute (NCI) Recruiting Wed, 07 Jun 2017 12:00:00 EDT First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.Condition: Breast NeoplasmsIntervention: Drug: Palbociclib + endocrine therapy Sponsor: Pfizer Recruiting Tue, 23 Feb 2021 12:00:00 EST A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)Conditions: Metastatic Breastcancer; Estrogen Receptor Positive Breast Cancer; Estrogen Receptor Negative Neoplasm; Progesterone Receptor Positive Tumor; Progesterone Receptor Negative Neoplasm; Androgen Receptor Gene OverexpressionIntervention: Drug: DHEA Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori Terminated Wed, 04 Dec 2013 12:00:00 EST Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer PatientsCondition: Breast CancerInterventions: Drug: Epirubicin; Drug: Cyclophosphamide; Drug: Docetaxel; Drug: Exemestane; Drug: Goserelin; Drug: Carboplatin Sponsors: Spanish Breast Cancer Research Group; Pfizer Completed Wed, 07 Feb 2007 12:00:00 EST Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant ExposureConditions: Breast Cancer; Estrogen Receptor Positive Tumor; Menopause; Hormone AntagonistInterventions: Drug: Immune-attractant; Drug: Durvalumab; Procedure: Biopsy Sponsors: UNICANCER; Breast International Group Completed Tue, 20 Dec 2016 12:00:00 EST Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast CancerCondition: Breast CancerInterventions: Drug: Palbociclib; Drug: Aromatase Inhibitor Sponsors: Dana-Farber Cancer Institute; Pfizer Completed Mon, 20 Jan 2014 12:00:00 EST
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast CancerCondition: Breast CancerInterventions: Drug: Everolimus; Drug: Exemestane; Drug: Tamoxifen; Drug: Fulvestrant; Drug: Anastrozole; Drug: Letrozole; Drug: Toremifine Sponsors: SCRI Development Innovations, LLC; Novartis Completed Mon, 17 Nov 2014 12:00:00 EST Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast CancerConditions: Postmenopausal Women; Locally Advanced Metastatic Breast Cancer; Metastatic Breast CancerInterventions: Drug: Everolimus; Drug: Letrozole Sponsor: Novartis Pharmaceuticals Completed Mon, 01 Nov 2010 12:00:00 EDT A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast CancerConditions: ER+ Breast Cancer; HER2-negative Breast CancerInterventions: Drug: Palbociclib 125Mg Tab; Drug: Fulvestrant injection; Drug: Tamoxifen; Drug: Letrozole; Drug: Exemestane; Drug: Anastrozole Sponsors: Royal Marsden NHS Foundation Trust; Pfizer; AstraZeneca; Institute of Cancer Research, United Kingdom; UNICANCER; Gustave Roussy, Cancer Campus, Grand Paris Not yet recruiting Mon, 02 Aug 2021 12:00:00 EDT Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast CancerCondition: Breast CancerInterventions: Drug: Capecitabine; Drug: aromatase Inhibitors (AIs) Sponsor: Fudan University Unknown status Fri, 16 Aug 2013 12:00:00 EDT Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or LetrozoleConditions: Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast CancerInterventions: Dietary Supplement: omega-3 fatty acid supplement; Other: Placebo; Other: Clinical assessments; Other: Assessment of therapy complications; Procedure: Magnetic Resonance Imaging; Procedure: Correlative/special studies Sponsors: Ohio State University Comprehensive Cancer Center; Cancer and Leukemia Group B Active, not recruiting Wed, 23 Nov 2011 12:00:00 EST Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or AnastrozoleCondition: Breast CancerIntervention: Procedure: mammography Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); NCIC Clinical Trials Group Completed Fri, 21 Apr 2006 12:00:00 EDT Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast CancerConditions: Anxiety Disorder; Breast Cancer; Depression; Fatigue; Hot Flashes; Pain; Sleep DisordersInterventions: Procedure: acupuncture therapy; Procedure: sham intervention Sponsors: University of Maryland, College Park; National Cancer Institute (NCI); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Completed Mon, 24 Mar 2008 12:00:00 EDT Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBCCondition: Metastatic Breast CancerInterventions: Drug: Palbociclib; Drug: Endocrine therapy (non IMP) Sponsor: MedSIR Completed Mon, 12 Jun 2017 12:00:00 EDT Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast CancerCondition: Breast CancerInterventions: Drug: anastrozole; Drug: cyclophosphamide; Drug: exemestane; Drug: letrozole; Drug: methotrexate; Drug: prednisolone Sponsor: National Cancer Centre, Singapore Unknown status Mon, 02 Jun 2008 12:00:00 EDT Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer PatientsCondition: Breast CancerInterventions: Drug: Neoadjuvant endocrine therapy; Drug: Neoadjuvant chemotherapy Sponsor: Ruijin Hospital Terminated Tue, 25 Aug 2015 12:00:00 EDT
Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node MetastasesConditions: Early-Stage Breast Carcinoma; Estrogen Receptor Positive TumorInterventions: Drug: Paclitaxel; Drug: Tamoxifen + Palbociclib; Drug: Aromatase Inhibitor + Palbociclib; Drug: Goserelin + Aromatase Inhibitor + Palbociclib Sponsor: Thomas Hatschek Active, not recruiting Fri, 13 Nov 2015 12:00:00 EST Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBCConditions: Breast Cancer; Invasive Breast Cancer; ER-Negative PR-Negative HER2-Negative Breast CancerIntervention: Drug: Entinostat Sponsors: UNC Lineberger Comprehensive Cancer Center; Syndax Pharmaceuticals; National Cancer Institute (NCI) Terminated Tue, 05 Dec 2017 12:00:00 EST Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical TrialConditions: Breast Cancer; OsteoporosisInterventions: Dietary Supplement: calcium carbonate; Dietary Supplement: calcium citrate; Dietary Supplement: cholecalciferol; Drug: alendronate sodium; Drug: calcium gluconate; Drug: risedronate sodium; Other: laboratory biomarker analysis; Procedure: dual x-ray absorptometry Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Southwest Oncology Group Completed Thu, 20 Jul 2006 12:00:00 EDT Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast CancerConditions: HER-2 Positive Breast Cancer; Estrogen Receptor Positive Breast CancerInterventions: Drug: palbociclib; Drug: trastuzumab; Drug: pertuzumab; Drug: letrozole; Drug: Anastrozole; Drug: Exemestane; Drug: Fulvestrant Sponsors: Alliance Foundation Trials, LLC.; Pfizer; German Breast Group; Fondazione Michelangelo; PrECOG, LLC.; Breast Cancer Trials, Australia and New Zealand; Syneos Health; SOLTI Breast Cancer Research Group; UNICANCER Active, not recruiting Fri, 28 Oct 2016 12:00:00 EDT Investigating Patient Satisfaction With Oral Anti-cancer Treatment in Patients With Hormone-receptor Positive, HER2-receptor Negative, Advanced Breast CancerCondition: ER Positive, HER2 Negative Breast Cancer NeoplasmsIntervention: Sponsors: KU Leuven; Novartis Unknown status Tue, 23 Aug 2016 12:00:00 EDT Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication UptakeCondition: Breast CancerIntervention: Genetic: Polygenic Risk Score Sponsors: Mayo Clinic; CancerCare Manitoba Completed Fri, 07 Aug 2015 12:00:00 EDT Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.Condition: Breast Cancer Stage IVInterventions: Drug: Palbociclib; Drug: Ribociclib; Drug: Abemaciclib; Drug: Letrozole; Drug: Anastrozole; Drug: Tamoxifen; Drug: Fulvestrant; Drug: Exemestane; Drug: Alpelisib Sponsor: Blokhin's Russian Cancer Research Center Recruiting Wed, 21 Apr 2021 12:00:00 EDT Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast CancerCondition: Breast CancerInterventions: Drug: Endocrine therapy combined with trastuzumab; Drug: Chemotherapy combined with trastuzumab Sponsor: Sun Yat-sen University Completed Wed, 25 Sep 2013 12:00:00 EDT Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast CancerCondition: Breast CancerInterventions: Drug: TOL2506; Drug: Tamoxifen; Drug: Letrozole Tablets; Drug: Anastrozole Tablets; Drug: Exemestane Tablets Sponsor: Tolmar Inc. Recruiting Fri, 28 May 2021 12:00:00 EDT Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor TherapyCondition: Breast CancerInterventions: Drug: anastrozole; Drug: exemestane; Drug: fulvestrant; Drug: lapatinib ditosylate; Drug: letrozole; Other: placebo Sponsor: Gruppo Italiano Mammella (GIM) Unknown status Mon, 02 Jun 2008 12:00:00 EDT
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast CancerCondition: Breast CancerInterventions: Drug: Ribociclib; Drug: Adjuvant endocrine therapy; Drug: Placebo Sponsor: Novartis Pharmaceuticals Completed Mon, 13 Mar 2017 12:00:00 EDT A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has SpreadCondition: Breast NeoplasmsInterventions: Drug: LY2835219; Drug: Letrozole; Drug: Anastrozole; Drug: Tamoxifen; Drug: Exemestane; Drug: Everolimus; Drug: Trastuzumab; Drug: LY3023414; Drug: Fulvestrant; Drug: Pertuzumab; Drug: Loperamide; Drug: Endocrine therapy Sponsor: Eli Lilly and Company Active, not recruiting Thu, 06 Feb 2014 12:00:00 EST Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive TumorsConditions: Early-Stage Breast Carcinoma; Hormone Receptor Positive TumorInterventions: Drug: Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelin; Drug: Palbociclib Sponsor: Thomas Hatschek Active, not recruiting Fri, 30 Oct 2015 12:00:00 EDT Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast CancerCondition: Breast Cancer RecurrentInterventions: Drug: Palbociclib 125mg; Drug: Standard endocrine therapy Sponsors: International Breast Cancer Study Group; Pfizer Recruiting Tue, 29 Jan 2019 12:00:00 EST Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast CancerCondition: Hormone-sensitive, HER-2 Negative Metastatic Breast CancerInterventions: Drug: MEDI-573; Drug: Aromatase Inhibitor Sponsor: MedImmune LLC Completed Wed, 05 Oct 2011 12:00:00 EDT PTC299 and Hormonal Agent for Treatment of Metastatic Breast CancerCondition: Metastatic Breast CancerIntervention: Drug: PTC299 Sponsors: PTC Therapeutics; United States Department of Defense Completed Mon, 30 Jul 2007 12:00:00 EDT Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine TherapyCondition: Breast NeoplasmInterventions: Drug: Palbociclib; Drug: Fulvestrant; Drug: Anastrozole; Drug: Letrozole; Drug: Exemestane Sponsors: Palleos Healthcare GmbH; WSG WOMEN´S HEALTHCARE STUDY GROUP; Cankado Service GmbH; Pfizer; AGO-TraFo; AGO-B; Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V. Active, not recruiting Tue, 18 Jul 2017 12:00:00 EDT Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT)Condition: Early-stage Breast CancerIntervention: Combination Product: Endocrine Therapy and Radiotherapy Sponsor: Ottawa Hospital Research Institute Active, not recruiting Tue, 14 May 2019 12:00:00 EDT Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal DatabaseCondition: Breast CancerInterventions: Other: Sample collection; Behavioral: Patient-reported outcomes Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Susan G. Komen Breast Cancer Foundation Active, not recruiting Mon, 09 Sep 2013 12:00:00 EDT Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast CancerConditions: Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast CancerInterventions: Drug: exemestane; Drug: triptorelin pamoate; Drug: capecitabine; Drug: methotrexate; Drug: vinorelbine tartrate; Drug: paclitaxel; Procedure: therapeutic conventional surgery; Radiation: radiation therapy; Other: laboratory biomarker analysis Sponsors: University of Washington; National Cancer Institute (NCI) Terminated Mon, 19 Sep 2005 12:00:00 EDT
Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer PatientsCondition: Breast NeoplasmsInterventions: Drug: Perjeta Injectable Product; Drug: Herceptin; Drug: Tamoxifen; Drug: Paclitaxel; Drug: Epirubicin; Drug: Cyclophosphamide; Drug: Anastrozole; Drug: Letrozole; Drug: Exemestane; Drug: Leuprorelin acetate; Drug: Goserelin; Drug: Leuporelin acetate; Diagnostic Test: Biopsy; Procedure: Surgery Sponsors: Palleos Healthcare GmbH; Roche Pharma AG; WSG WOMEN´S HEALTHCARE STUDY GROUP; Cankado Service GmbH Active, not recruiting Tue, 05 Sep 2017 12:00:00 EDT A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast CancerCondition: Breast NeoplasmsInterventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody; Drug: Bevacizumab; Drug: Entinostat; Drug: Exemestane; Drug: Fulvestrant; Drug: Ipatasertib; Drug: Tamoxifen; Drug: Abemaciclib Sponsor: Hoffmann-La Roche Recruiting Tue, 12 Sep 2017 12:00:00 EDT Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast CancerCondition: Breast CancerInterventions: Genetic: Single nucleotide polymorphism (SNP); Other: high performance liquid chromatography; Other: measurements by DXA; Other: questionnaire administration Sponsors: Mayo Clinic; National Cancer Institute (NCI) Completed Mon, 30 Jan 2006 12:00:00 EST Detect V / CHEVENDO (Chemo vs. Endo)Condition: Metastatic Breast CancerInterventions: Drug: pertuzumab; Drug: Trastuzumab; Drug: Capecitabine; Drug: Paclitaxel; Drug: Vinorelbine; Drug: Docetaxel; Drug: Exemestane; Drug: Letrozole; Drug: Anastrozole; Drug: Fulvestrant; Drug: Ribociclib; Drug: nab-Paclitaxel; Drug: eribulin; Drug: leuprorelin; Drug: goserelin Sponsors: Prof. W. Janni; Roche Pharma AG; Novartis Pharmaceuticals; Eisai GmbH; Celgene Corporation Recruiting Mon, 26 Jan 2015 12:00:00 EST Oral Health in Breast Cancer Survivors on Aromatase InhibitorsConditions: Periodontal Disease; Quality of LifeIntervention: Sponsors: University of Michigan; National Institute of Dental and Craniofacial Research (NIDCR) Completed Wed, 26 Sep 2012 12:00:00 EDT Breast Cancer Treatment Based on Organ-like CultureCondition: Breast Cancer OrganoidsInterventions: Drug: Trastuzumab; Drug: Doxorubicin Hydrochloride; Drug: Epirubicin hydrochloride; Drug: Fluorouracil; Drug: Paclitaxel; Drug: Gemcitabine; Drug: Cisplatin; Drug: Recombinant Human Endostatin; Drug: Pirarubicin hydrochloride; Drug: Pyrrolidine; Drug: Ixabepilone; Drug: Tamoxifen citrate; Drug: Vinorelbine tartrate; Drug: Carboplatin; Drug: Methotrexate; Drug: Eribulin mesylate; Drug: Toremifene citrate; Drug: Anastrozole; Drug: Letrozole; Drug: Exemestane; Drug: Fulvestrant; Drug: Olaparib; Drug: Bevacizumab; Drug: Apatinib mesylate; Drug: Pattozumab; Drug: Capecitabine; Drug: Ear particles; Drug: Aidi Injection; Drug: Cyclophosphamide Sponsor: Xijing Hospital Enrolling by invitation Wed, 24 Apr 2019 12:00:00 EDT Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast CancerConditions: Breast Cancer Female; Locally Advanced Breast Cancer; Hormone Receptor Positive Malignant Neoplasm of BreastIntervention: Drug: Abemaciclib, durvalumab and aromatase inhibitor Sponsors: Alison Stopeck; Eli Lilly and Company; AstraZeneca Withdrawn Thu, 12 Sep 2019 12:00:00 EDT Breast Cancer Women on Aromatase Inhibitors TreatmentConditions: Osteoporosis; Osteoporosis Fracture; Arthralgia GeneralizedIntervention: Drug: bisphosphonate Sponsors: Parc de Salut Mar; Instituto de Salud Carlos III Recruiting Tue, 22 Jan 2019 12:00:00 EST Collaborative Seamless Care in Oncology : Measure and Reinforce Safety and Adherence to Oral Cancer TreatmentCondition: CancerIntervention: Sponsors: Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland; Centre Hospitalier Universitaire Vaudois Unknown status Fri, 10 Jun 2011 12:00:00 EDT Prediction of Everolimus-induced Interstitial Lung DiseaseCondition: Breast NeoplasmsIntervention: Sponsor: Radboud University Completed Thu, 07 Nov 2013 12:00:00 EST
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast CancerCondition: Metastatic Breast CancerInterventions: Biological: IMC-A12 (cixutumumab); Drug: tamoxifen; Drug: Anastrozole; Drug: Letrozole; Drug: Exemestane; Drug: Fulvestrant Sponsor: Eli Lilly and Company Completed Wed, 06 Aug 2008 12:00:00 EDT Evaluation of Oral Care to Prevent Oral Mucositis in ER Positive MBC Patients Treated With Everolimus: Phase 3 RCTCondition: Breast CancerInterventions: Procedure: Oral management; Drug: Everolimus Sponsors: Comprehensive Support Project for Oncology Research; Novartis Pharmaceuticals Completed Tue, 03 Mar 2015 12:00:00 EST DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCsConditions: HER2-negative Metastatic Breast Cancer; HER2-positive Circulating Tumor CellsInterventions: Drug: standard chemo- or endocrine therapy; Drug: standard chemo- or endocrine therapy + Lapatinib Sponsor: Prof. W. Janni Unknown status Thu, 14 Jun 2012 12:00:00 EDT MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast CancerCondition: Breast Cancer MetastaticInterventions: Drug: MCLA-128; Drug: Trastuzumab; Drug: Vinorelbine; Drug: Endocrine therapy Sponsor: Merus N.V. Active, not recruiting Thu, 26 Oct 2017 12:00:00 EDT Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk ScoreCondition: Breast CancerIntervention: Drug: Everolimus Sponsors: Yale University; Novartis Pharmaceuticals Completed Wed, 10 Sep 2014 12:00:00 EDT A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast CancerConditions: HER2-positive Breast Cancer; Invasive Carcinoma of the Breast; Breast Cancer; Node Negative Breast Cancer; Micrometastasis Breast Cancer; Hormone Receptor Positive Breast CancerInterventions: Combination Product: Pertuzumab+TRASTUZUMAB; Drug: ADJUVANT ENDOCRINE THERAPY Sponsors: Dana-Farber Cancer Institute; Genentech, Inc. Recruiting Wed, 30 Sep 2020 12:00:00 EDT Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine TherapyCondition: Breast CancerIntervention: Other: endocrine therapy Sponsor: Shengjing Hospital Recruiting Mon, 20 Jul 2020 12:00:00 EDT Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast CancerConditions: Breast Cancer; Recurrent Breast Cancer; Stereotactic Body Radiotherapy; Estrogen Receptor Positive Tumor; Her2-negative Tumor; SurgeryInterventions: Procedure: Surgical resection; Radiation: Stereotactic body radiotherapy; Procedure: Radiofrequency ablation Sponsors: Gangnam Severance Hospital; Severance Hospital; Samsung Medical Center; Asan Medical Center Recruiting Fri, 23 Nov 2018 12:00:00 EST Efficacy and Safety of Leuprorelin 3M in Premenopausal Women With Hormone Receptor-positive Breast CancerCondition: Hormone Receptor-positive Breast CancerIntervention: Drug: AI or TAM Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not yet recruiting Tue, 18 May 2021 12:00:00 EDT Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer PatientsCondition: Breast CancerIntervention: Sponsor: Fudan University Completed Thu, 31 May 2018 12:00:00 EDT
Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)Condition: Breast CancerInterventions: Drug: capecitabine and trastuzumab; Drug: endocrine therapy and trastuzumab Sponsor: Fudan University Not yet recruiting Tue, 12 May 2020 12:00:00 EDT Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast CancerCondition: Breast CancerInterventions: Drug: Capecitabine; Drug: endocrine therapy Sponsor: Zhejiang Cancer Hospital Recruiting Sun, 02 Jul 2017 12:00:00 EDT the Effect of Clomiphene Citrate Plus Estradiol Valerate Versus Letrozole on Endometrial Thickness and Pregnancy Rate in Infertile WomenConditions: Endometrial Thickness; Pregnancy RateInterventions: Drug: Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt; Drug: letrozole (Femara; Novartis pharma AG, Basle, Switzerland) Sponsor: Laylay Mohammed Khalleefah Alhibshi Completed Fri, 06 Nov 2020 12:00:00 EST Genomic Based Assignment of Therapy in Advanced Urothelial CarcinomaConditions: Urothelial Carcinoma; Bladder Cancer; Urinary Bladder NeoplasmsInterventions: Drug: 75 approved agents; Other: COXEN Sponsor: National Cancer Institute (NCI) Completed Thu, 02 Jun 2016 12:00:00 EDT Dose EScalation Induction of EvERolimusConditions: Breast Cancer; Hormone Receptor Positive TumorInterventions: Drug: 3 weeks Dose Induction of Everolimus; Drug: 3 weeks Conventional Everolimus Dosing; Drug: Open Label Phase with conventional 10mg Everolimus Dosing week 4-24; Drug: Standard Care after 24 weeks Sponsors: German Breast Group; Novartis Recruiting Thu, 12 Mar 2015 12:00:00 EDT Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer SurvivorsConditions: Breast Cancer; XerostomiaIntervention: Sponsor: University of Michigan Completed Fri, 07 Jan 2011 12:00:00 EST Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast CancerCondition: Breast CancerInterventions: Drug: Ribociclib; Drug: Placebo; Drug: Adjuvant endocrine therapy Sponsor: Novartis Pharmaceuticals Withdrawn Thu, 16 Mar 2017 12:00:00 EDT Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast CancerCondition: Neoplasms, BreastInterventions: Drug: Lapatinib; Biological: Trastuzumab; Drug: Aromatase Inhibitors (AIs) Sponsor: Novartis Pharmaceuticals Terminated Mon, 11 Aug 2014 12:00:00 EDT A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Condition: Early Breast CancerInterventions: Drug: Giredestrant; Drug: Endocrine Therapy of Physician's Choice; Drug: LHRH Agonist Sponsor: Hoffmann-La Roche Recruiting Wed, 14 Jul 2021 12:00:00 EDT A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial CancerConditions: Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; Endometrial CancerInterventions: Drug: LY3484356; Drug: Abemaciclib; Drug: Everolimus; Drug: Alpelisib; Drug: Trastuzumab; Drug: Aromatase Inhibitor (AI) Sponsor: Eli Lilly and Company Recruiting Fri, 06 Dec 2019 12:00:00 EST
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast CancerCondition: Neoplasms, BreastInterventions: Drug: lapatinib; Drug: trastuzumab; Drug: Aromatase inhibitor Sponsors: Novartis Pharmaceuticals; GlaxoSmithKline Active, not recruiting Mon, 12 Jul 2010 12:00:00 EDT Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast CancerCondition: Metastatic Breast CancerInterventions: Drug: Palbociclib; Drug: Trastuzumab; Drug: Endocrine therapy; Drug: Chemotherapy; Drug: Antibody-Drug Conjugates Sponsor: SOLTI Breast Cancer Research Group Recruiting Tue, 19 May 2015 12:00:00 EDT Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast CancerCondition: Neoplasms, BreastInterventions: Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A; Drug: Placebo; Drug: Aromatase inhibitor; Drug: 5-Fluorouracil; Drug: Carboplatin AUC; Drug: Cyclophosphamide; Drug: Docetaxel; Drug: Doxorubicin; Drug: Epirubicin; Drug: Paclitaxel; Drug: Trastuzumab Sponsor: GlaxoSmithKline Terminated Wed, 13 Oct 2010 12:00:00 EDT |